It’s not all checkpoints all the time at Bristol-Myers Squibb. The big biotech has been ramping up an ambitious effort in fibrosis and NASH and this morning it’s taking the wraps off another deal in the field, paying $100 million to Japan’s Nitto Denko for an early-stage drug candidate that now becomes part of their portfolio.
The key drug in this package deal is ND-L02-s0201, a siRNA that is designed to inhibit heat shock protein 47. By hitting HSP47, their investigators believe that they can cut the production of collagen that plays a role in fibrosis and NASH, while helping correct at least some of the damage that has already been done to patients.
The drug is undergoing a 5-week Phase Ib study now to give them a better idea of how the drug works for fibrosis caused by NASH, an epidemic fatty liver disease, and hepatitis C. And Bristol-Myers gets the rights to Nitto Denko’s portfolio in the field, bagging exclusive rights for fibrosis in a variety of diseases.
The deal includes milestones, which weren’t discussed in their statement.
Nitto Denko is a century-old diversified materials manufacturer based in Osaka with a newfound interest in diversifying into biotech. Early this year the company established a biotech subsidiary called Nitto BioPharma, with facilities in San Diego and plans to continue to pursue R&D in IPF and other diseases.
Bristol-Myers execs have been putting a brave face on their recent debacle in frontline non-small cell lung cancer for their PD-1 pioneer Opdivo. The late-stage failure left a bad scar, but the company points to its R&D work in fibrosis/NASH and heart failure as examples of a more diversified pipeline.
Back in August, 2015, the ambitious R&D group struck a $1.25 billion deal — $150 million up front — to gain an option to acquire Promedior if its mid-stage fibrosis program comes through.
Bristol-Myers has its sights set on PRM-151, a recombinant form of human pentraxin-2 protein in development for idiopathic pulmonary fibrosis and myelofibrosis. The company scored another provisional buyout agreement for Denmark’s Galecto in 2014, agreeing to pay up to $444 million for the company. That deal centered on TD139, an inhibitor of galectin-3, which binds to carbohydrate structures, playing a role in IPF that can be derailed by this new drug. TD139 joined BMS-986020, a lysophosphatidic acid 1 (LPA1) receptor antagonist also in studies for fibrosis. Bristol-Myers also struck research deals with the California Institute for Biomedical Research (Calibr) and The Medical University of South Carolina.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 24,000+ biopharma pros who read Endpoints News by email every day.Free Subscription